After two and a half years providing COVID-19 testing services to New England and beyond – including over 1.6 million tests – JAX’s Clinical Genomics Laboratory has suspended COVID-19 testing as of Friday, July 29, 2022, in alignment with the significant decrease in COVID-19 PCR testing demand. We will continue to monitor the pandemic and testing needs, and are prepared to reinstate testing services should demand increase. We are grateful to our community partners for supporting and collaborating with the JAX CLIA lab on this important endeavor.
While testing and sequencing services are no longer JAX’s focus at present, we are continuing our vital COVID-19 research, including the investigating the biological complexities of COVID, long COVID, and developing mouse models for the study of this virus.
The JAX CLIA lab’s focus has now returned to serving the oncology community with complex tumor profiling assays that help cancer patients and their physicians learn about specific tumors and provide insight into the most promising treatment options. We are proud of the continued role we play in improving human health and empowering the global biomedical community in our shared quest to improve human health.
Recent News from JAX
-
Press Release
December 02, 2020
JAX nominated as a healthcare hero
The Hartford Business Journal has recognized JAX among its 2020 Health Care Heroes in the Innovation category, recognizing an organization that has made a positive advancement in medical care or medical science.
-
Search Magazine
May 19, 2020
Help for heroes
Coronavirus testing at The Jackson Laboratory helps officials track and prevent transmission of COVID-19. To date, JAX has processed more than one million tests.
-
Research HighlightAugust 18, 2022Defining long COVID with patient data
Peter Robinson is working with hospital systems across the U.S. to pool COVID patient data and better define the scope of the long COVID problem and provide better clinical insight for patients. -
Featured ArticleNovember 03, 2021Examining the Delta COVID-19 variant and more
What is the status of the SARS-CoV-2 variant Delta now? What other variants might emerge? And when can we finally move forward into the "new normal?" -
Research HighlightSeptember 20, 2021Variable COVID-19 pathology depends on host genetic backgrounds
Mice with different genetic backgrounds exhibit highly variable responses to SARS-CoV-2 infection, mirroring the large differences in COVID-19 disease severity seen in humans. -
Press ReleaseJune 01, 2021JAX helps brief CT legislature on COVID-19 variants
Dr. Mark Adams of JAX and Dr. Nathan Grubaugh of the Yale School of Public Health spoke to legislators about how COVID s being monitored, which variants are present to date, and what we know about how the mutations are changing the properties of the virus itself.
-
Tech CornerJanuary 14, 2022The challenge of Omicron: exploring the new variant
With the arrival of the Omicron COVID-19 variant, we take the time to examine how it got here and what the future holds for this and other variants. -
Research HighlightSeptember 22, 2021JAX is tracking sub-genomic SARS-CoV-2 variation
Chia-Lin Wei looked at SARS-CoV-2 RNA genomes and sub-genomic viral RNA in symptomatic and asymptomatic patients and found distinct, consistent differences between the patient groups. The findings have important implications for developing better COVID-19 risk mitigation and clinical strategies. -
Blog PostJuly 26, 2021Using wearables and clinical data to fight COVID-19
Many of us use wearable devices and health trackers, but how can this collected data be used to keep us healthy and disease free? -
Featured ArticleMay 12, 2021Perfect score for JAX testing
The Jackson Laboratory’s clinical testing lab in Farmington, Conn., has processed an astonishing 1.5 million COVID-19 tests since March 2020. That quantity is backed up by quality: The College of American Pathologists (CAP) has renewed its accreditation of the lab, following an inspection with a perfect score.